Early cerebral amyloid-β accumulation and hypermetabolism are associated with subtle cognitive deficits before accelerated cerebral atrophy
- PMID: 38102439
- PMCID: PMC10828321
- DOI: 10.1007/s11357-023-01031-w
Early cerebral amyloid-β accumulation and hypermetabolism are associated with subtle cognitive deficits before accelerated cerebral atrophy
Abstract
Aims: Alzheimer's disease (AD) is characterized by the accumulation of amyloid beta (Aβ) in the brain. The deposition of Aβ is believed to initiate a detrimental cascade, including cerebral hypometabolism, accelerated brain atrophy, and cognitive problems-ultimately resulting in AD. However, the timing and causality of the cascade resulting in AD are not yet fully established. Therefore, we examined whether early Aβ accumulation affects cerebral glucose metabolism, atrophy rate, and age-related cognitive decline before the onset of neurodegenerative disease.
Methods: Participants from the Metropolit 1953 Danish Male Birth Cohort underwent brain positron emission tomography (PET) imaging using the radiotracers [11C]Pittsburgh Compound-B (PiB) (N = 70) and [18F]Fluorodeoxyglucose (FDG) (N = 76) to assess cerebral Aβ accumulation and glucose metabolism, respectively. The atrophy rate was calculated from anatomical magnetic resonance imaging (MRI) scans conducted presently and 10 years ago. Cognitive decline was examined from neurophysiological tests conducted presently and ten or 5 years ago.
Results: Higher Aβ accumulation in AD-critical brain regions correlated with greater visual memory decline (p = 0.023). Aβ accumulation did not correlate with brain atrophy rates. Increased cerebral glucose metabolism in AD-susceptible regions correlated with worse verbal memory performance (p = 0.040).
Conclusions: Aβ accumulation in known AD-related areas was associated with subtle cognitive deficits. The association was observed before hypometabolism or accelerated brain atrophy, suggesting that Aβ accumulation is involved early in age-related cognitive dysfunction. The association between hypermetabolism and worse memory performance may be due to early compensatory mechanisms adapting for malfunctioning neurons by increasing metabolism.
Keywords: Aging; Amyloid; Atrophy; Cerebral glucose metabolism; Cognition; PET imaging.
© 2023. The Author(s).
Conflict of interest statement
The authors declare that they have no conflicts of interest.
Figures




Similar articles
-
The cerebral blood flow response to neuroactivation is reduced in cognitively normal men with β-amyloid accumulation.Alzheimers Res Ther. 2025 Jan 4;17(1):4. doi: 10.1186/s13195-024-01652-z. Alzheimers Res Ther. 2025. PMID: 39754275 Free PMC article.
-
Parallel ICA of FDG-PET and PiB-PET in three conditions with underlying Alzheimer's pathology.Neuroimage Clin. 2014 Mar 19;4:508-16. doi: 10.1016/j.nicl.2014.03.005. eCollection 2014. Neuroimage Clin. 2014. PMID: 24818077 Free PMC article.
-
Urinary formic acid is associated with cerebral amyloid deposition and glucose metabolism in memory clinic patients.J Alzheimers Dis. 2025 Feb;103(4):1102-1111. doi: 10.1177/13872877241309117. Epub 2025 Jan 10. J Alzheimers Dis. 2025. PMID: 39791247
-
Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study.Lancet Neurol. 2013 Apr;12(4):357-67. doi: 10.1016/S1474-4422(13)70044-9. Epub 2013 Mar 8. Lancet Neurol. 2013. PMID: 23477989
-
Brain fuel metabolism, aging, and Alzheimer's disease.Nutrition. 2011 Jan;27(1):3-20. doi: 10.1016/j.nut.2010.07.021. Epub 2010 Oct 29. Nutrition. 2011. PMID: 21035308 Free PMC article. Review.
Cited by
-
P300 Latency with Memory Performance: A Promising Biomarker for Preclinical Stages of Alzheimer's Disease.Biosensors (Basel). 2024 Dec 15;14(12):616. doi: 10.3390/bios14120616. Biosensors (Basel). 2024. PMID: 39727881 Free PMC article.
-
Behavioral variant frontotemporal dementia (bvFTD): PET biomarker characterization of metabolism (18F-FDG), amyloid (11C-PIB) and tau (18F-AV1451) and its clinical correlate - analysis of a cohort from Argentina.Alzheimers Dement. 2025 Apr;21(4):e70187. doi: 10.1002/alz.70187. Alzheimers Dement. 2025. PMID: 40271555 Free PMC article.
-
The Role of Magnesium in Depression, Migraine, Alzheimer's Disease, and Cognitive Health: A Comprehensive Review.Nutrients. 2025 Jul 4;17(13):2216. doi: 10.3390/nu17132216. Nutrients. 2025. PMID: 40647320 Free PMC article. Review.
-
Nebulized seabuckthorn seed oil inhalation attenuates Alzheimer's disease progression in APP/PS1 mice.Sci Rep. 2025 Feb 21;15(1):6368. doi: 10.1038/s41598-025-89747-x. Sci Rep. 2025. PMID: 39984555 Free PMC article.
-
The cerebral blood flow response to neuroactivation is reduced in cognitively normal men with β-amyloid accumulation.Alzheimers Res Ther. 2025 Jan 4;17(1):4. doi: 10.1186/s13195-024-01652-z. Alzheimers Res Ther. 2025. PMID: 39754275 Free PMC article.
References
-
- Chetelat G, Arbizu J, Barthel H, Garibotto V, Law I, Morbelli S, van de Giessen E, Agosta F, Barkhof F, Brooks DJ, Carrillo MC, Dubois B, Fjell AM, Frisoni GB, Hansson O, Herholz K, Hutton BF, Jack CR, Lammertsma AA, Landau SM, Minoshima S, Nobili F, Nordberg A, Ossenkoppele R, Oyen WJ, Perani D, Rabinovici GD, Scheltens P, Villemagne VL, Zetterberg H, Drzezga A. Amyloid-PET and 18F-FDG-PET in the diagnostic investigation of Alzheimer’s disease and other dementias. Lancet Neurol. 2020;19(11):951–962. - PubMed
-
- Dubois B, Villain N, Frisoni GB, Rabinovici GD, Sabbagh M, Cappa S, Bejanin A, Bombois S, Epelbaum S, Teichmann M, Habert MO, Nordberg A, Blennow K, Galasko D, Stern Y, Rowe CC, Salloway S, Schneider LS, Cummings JL, Feldman HH. Clinical diagnosis of Alzheimer’s disease: recommendations of the International Working Group. Lancet Neurol. 2021;20(6):484–496. doi: 10.1016/S1474-4422(21)00066-1. - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical